The table below shows Travere Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$40.37M
-$42.19M
-$119.00M
-$81.12M
-$55.32M
-$26.47M
Capital expenditure
-
-
$0.00
$630.00K
$131.00K
$4.50M
Investing cash flow
$21.55M
$41.29M
$104.90M
-$37.04M
$33.16M
-$105.71M
Dividends paid
-
-
-
-
TVTX operating cash flow (10-K history)
Travere Therapeutics, Inc. reported operating cash flow of $37.78M for fiscal year 2025. That is up 115.9% from -$237.47M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$3.44M (FY 2016) to $37.78M. Figures come from the company's audited annual reports as filed with the SEC.